| Literature DB >> 31294004 |
Mahrrouz Caputo1,2, Heike Raupach-Rosin1, André Karch1,3,4, Michael Borte5, Irina Lehmann6,7, Uwe Gerd Liebert8, Marie Standl9, Joachim Heinrich9,10, Rafael T Mikolajczyk3,11.
Abstract
The evidence for non-specific effects (NSE) of vaccinations on all-cause morbidity and mortality among children is growing. However, our understanding of the underlying mechanisms is still limited. One hypothesis is that NSE are mediated by antibody titers. We used data of 2,123 children from the population-based birth cohort study LISA conducted in Germany to explore whether routine childhood vaccinations and the individual infection history in the first 2 years of life are associated with unrelated antibody titers. We selected 19 exposures (infections and vaccinations) and investigated their association with levels of 12 IgG antibody titers at the age of 2 years. Based on univariable analyses (ANOVA), we identified 21 crude associations between exposures and titers (p < 0.05), while 11 (95%-CI: 6, 17) spurious associations were expected due to multiple testing. In exploratory multivariable analyses, we observed associations between seven investigated IgG titers and 10 exposures; either administered vaccines [e.g., higher anti-hRSV IgG titer in BCG-vaccinated children (regression-coefficient in standard-deviation-units: 0.38; 95%-CI: 0.12, 0.65)] or infections [e.g., higher anti-measles IgG titer in children with reported chickenpox (0.44; 95%-CI: 0.08, 0.80)]. Our results indicate the existence of associations between immunogenic exposures and unrelated antibody titers. Further studies investigating the underlying immunological mechanisms are required.Entities:
Keywords: humoral response; immune response; infectious diseases; non-specific effects; vaccinations
Year: 2019 PMID: 31294004 PMCID: PMC6603196 DOI: 10.3389/fped.2019.00254
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1Flow Chart of included children by investigated IgG titers. (1) Of these 2,661 completed the 2-years-questionnaire. (2) Of some children the serum was insufficient for detection of certain IgG titers. (3) One child with corresponding measles infection excluded.
Baseline characteristics of participants in the LISA study.
| Sex of child, % | ||
| Female | 48.8 (1,510/3,094) | 47.5 (1,009/2,123) |
| Male | 51.2 (1,584/3,094) | 52.5 (1,114/2,123) |
| Year of birth, % | ||
| 1997 | 1.3 (41/3,094) | 1.5 (31/2,123) |
| 1998 | 92.0 (2,845/3,094) | 92.0 (1,953/2,123) |
| 1999 | 6.7 (208/3,094) | 6.6 (139/2,123) |
| Median age of the mother at birth, y | ||
| 31 (28/34) | 31 (29/34) | |
| Education of parents, % | ||
| Low | 6.2 (188/3,057) | 4.2 (88/2,102) |
| Intermediate | 29.6 (906/3,057) | 27.4 (576/2,102) |
| High | 64.2 (1,963/3,057) | 68.4 (1,438/2,102) |
| Study location, % | ||
| Munich | 47.3 (1,464/3,094) | 48.5 (1,029/2,123) |
| Leipzig | 31.5 (976/3,094) | 30.5 (647/2,123) |
| Bad Honnef | 9.9 (306/3,094) | 11.2 (238/2,123) |
| Wesel | 11.3 (348/3,094) | 9.8 (209/2,123) |
| Provided questionnaires, % | ||
| Birth questionnaire | 100.0 (3,094/3,094) | 100.0 (2,123/2,123) |
| Half-year questionnaire | 91.3 (2,825/3,094) | 99.1 (2,104/2,123) |
| 1-year questionnaire | 88.4 (2,734/3,094) | 97.9 (2,078/2,123) |
| One-and-half year questionnaire | 87.5 (2,707/3,094) | 98.2 (2,085/2,123) |
| 2-years questionnaire | 86.0 (2,661/3,094) | 99.5 (2,113/2,123) |
Q1, first quartile (25%); Q3, third quartile (75%).
Children included with at least one available IgG titer of 12 selected antibody titers.
Low, without school-leaving certificate or lower secondary school certificate (<10 years); intermediate, secondary school certificate (= 10 years); high, general qualification for university entrance (>10 years).
Exposure to vaccinations and infections during first 2 years of life as well as during pregnancy of participants in the LISA study.
| Respiratory infection | 5.8 (123) | 16.8 (356) | 69.7 (1,480) | 4.9 (104) | 2.8 (60) |
| Pseudocroup | 2.0 (43) | 7.4 (157) | 1.5 (32) | 83.2 (1,767) | 5.8 (124) |
| Pertussis | 0.3 (7) | 0.2 (4) | 0.1 (2) | 93.6 (1,988) | 5.8 (122) |
| Roseola | 13.2 (280) | 14.2 (302) | 4.7 (100) | 61.2 (1,300) | 6.6 (141) |
| Chickenpox | 5.4 (115) | 11.3 (239) | 0.7 (15) | 77.1 (1,637) | 5.5 (117) |
| Diarrhea with or without fever | 11.4 (242) | 29.2 (620) | 19.0 (404) | 35.1 (745) | 5.3 (112) |
| Thrush in the mouth or diaper area | 19.5 (413) | 10.2 (217) | 8.6 (183) | 56.6 (1,201) | 5.1 (109) |
| Urinary tract infection | – | 2.7 (57) | – | 94.2 (2,000) | 3.1 (66) |
| Worm infection | 0 | 0.3 (6) | 0 | 94.5 (2,007) | 5.2 (110) |
| Scarlet fever | – | 2.4 (51) | – | 94.8 (2,012) | 2.8 (60) |
| Mumps | – | 0.1 (3) | – | 98.9 (2,100) | 0.9 (20) |
| Measles | – | 0.1 (2) | – | 99.0 (2,101) | 0.9 (20) |
| Rubella | – | 0.5 (11) | – | 98.5 (2,092) | 0.9 (20) |
| Tuberculosis (BCG) | 8.9 (189) | 0.5 (10) | 1.2 (25) | 39.1 (831) | 50.3 (1,068) |
| DTPPHIB | 12.4 (264) | 1.2 (26) | 72.8 (1,545) | 0.7 (15) | 12.9 (273) |
| Hepatitis B | 11.2 (238) | 5.0 (106) | 43.2 (916) | 14.9 (317) | 25.7 (546) |
| MMR | 1.5 (32) | 45.4 (964) | 4.1 (86) | 16.2 (344) | 32.8 (697) |
| Vaccination | 15.4 (326) | 84.4 (1,791) | 0.3 (6) | ||
| Infection | 13.3 (283) | 86.4 (1,834) | 0.3 (6) | ||
Only first year, only children vaccinated/infected within the first year of age; Only second year, only children vaccinated/infected within the second year of age; Both years, only children vaccinated/infected during both, first and second year of age; No infection/vaccination, no vaccination/infection in the first 2 years of life; Missing, missing values.
Includes pneumonia, otitis media, obstruct or spastic bronchitis, respiratory diseases and bronchitis.
Only asked in children aged 12–24 months.
Only asked in children aged 19–24 months.
Includes vaccinations against diphtheria, tetanus, polio, pertussis, and Haemophilus influenzae type b (HIB).
Includes vaccinations against mumps, measles, and rubella.
Children with incomplete data on vaccination against all three, mumps, measles and rubella, were classified as “Missing.”
Dichotomous-categorized variables.
Bivariate associations between infections, vaccinations, exposures during pregnancy, and IgG antibody titers of participants in the LISA study (p-values for F-test from ANOVA).
| Respiratory infection | 0.686 | 0.705 | 0.313 | 0.914 | 0.585 | 0.309 | 0.091 | 0.135 | 0.552 | 0.222 | n.a. | |
| Pseudocroup | 0.256 | 0.808 | 0.192 | 0.324 | 0.849 | 0.381 | 0.947 | 0.622 | 0.271 | 0.587 | 0.735 | |
| Pertussis | 0.611 | 0.732 | 0.370 | 0.341 | 0.624 | 0.418 | 0.947 | 0.503 | – | 0.206 | 0.113 | 0.251 |
| Roseola | 0.254 | 0.658 | 0.263 | n.a. | 0.620 | 0.976 | 0.312 | 0.435 | 0.656 | 0.827 | 0.566 | 0.798 |
| Chickenpox | 0.732 | 0.138 | 0.347 | 0.818 | 0.175 | 0.522 | 0.361 | 0.575 | 0.641 | 0.416 | 0.358 | |
| Diarrhea | 0.937 | 0.250 | 0.278 | 0.245 | 0.675 | 0.763 | 0.497 | 0.280 | 0.711 | 0.253 | 0.601 | 0.554 |
| Thrush in the mouth or diaper area | 0.219 | 0.817 | 0.526 | 0.697 | 0.383 | 0.414 | 0.091 | 0.742 | 0.191 | 0.932 | 0.154 | |
| Urinary tract infection | 0.792 | 0.864 | 0.352 | 0.913 | 0.427 | 0.863 | 0.356 | 0.481 | 0.308 | 0.386 | 0.908 | |
| Worm infection | – | 0.667 | 0.919 | 0.782 | 0.658 | 0.273 | 0.448 | 0.238 | – | 0.892 | 0.712 | 0.813 |
| Scarlet fever | 0.946 | 0.447 | 0.350 | 0.345 | 0.520 | 0.592 | 0.970 | 0.774 | 0.548 | 0.206 | 0.506 | 0.231 |
| Measles | – | – | 0.422 | 0.187 | 0.271 | – | – | – | n.a. | 0.963 | 0.068 | |
| Mumps | 0.940 | 0.362 | 0.082 | 0.565 | 0.181 | – | 0.819 | 0.408 | – | 0.054 | 0.946 | 0.726 |
| Rubella | 0.828 | 0.760 | 0.623 | 0.925 | 0.299 | 0.785 | – | 0.538 | 0.979 | 0.200 | ||
| Tuberculosis | 0.231 | 0.605 | 0.538 | 0.914 | 0.052 | 0.948 | 0.054 | 0.509 | 0.051 | |||
| DTPPHIB | 0.511 | 0.541 | 0.935 | 0.727 | 0.834 | 0.121 | 0.442 | 0.194 | 0.988 | |||
| Hepatitis B | 0.144 | 0.555 | 0.799 | 0.431 | 0.851 | 0.555 | 0.863 | 0.656 | 0.204 | |||
| MMR | 0.229 | 0.548 | 0.425 | 0.402 | 0.240 | 0.505 | 0.937 | 0.542 | 0.902 | n.a. | ||
| Vaccinations | 0.554 | 0.672 | 0.509 | 0.220 | 0.356 | 0.347 | 0.283 | 0.901 | 0.060 | 0.435 | ||
| Infections | 0.557 | 0.998 | 0.803 | 0.274 | 0.362 | 0.833 | 0.323 | 0.397 | 0.190 | 0.543 | ||
ADV, adenovirus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, human herpesvirus 6; HIB, Haemophilus influenzae type b; hPIV-3, human parainfluenza virus 3; hRSV, human respiratory syncytial virus; HSV, herpes simplex virus; MMR, combine vaccination against mumps measles and rubella; –, No p-value calculated, since no observation in this category; n.a., not analyzed, since only non-specific effects are analyzed; bold values indicates p <0.05.
Normalized and standardized antibody titers of children; reported p-value by ANOVA.
Four categories for exposures: only in first year, only in second year, in both years, and in neither of the 2 years of age (reference group); respectively for reported infectious disease or obtained vaccination.
Includes pneumonia, otitis media, obstruct or spastic bronchitis, respiratory diseases, and bronchitis.
Only asked in children aged 12–24 months.
Only asked in children aged 19–24 months.
Includes vaccination against diphtheria, tetanus, polio, pertussis, and HIB.
Vaccination/infection ever during pregnancy vs. vaccination/ infection never during pregnancy (dichotomized coded).
Only IgG titers of children with corresponding vaccination; children with corresponding infection were excluded.
While the specific viruses can cause respiratory infections and lead to a pseudocroup, they are not their single, or most common cause, and therefore, the exposure were kept in the analysis (none displayed a significant association with the respective IgG titer).
Bivariate associations between infections, vaccinations, exposures during pregnancy including missing values, and IgG antibody titers of participants in the LISA study (p-values for F-test from ANOVA).
| Respiratory infection | 0.696 | 0.801 | 0.339 | 0.419 | 0.190 | 0.405 | 0.154 | 0.179 | 0.656 | 0.321 | n.a. | |
| Pseudocroup | 0.158 | 0.914 | 0.279 | 0.202 | 0.664 | 0.340 | 0.818 | 0.774i | 0.441 | 0.497 | 0.055 | |
| Pertussis | 0.368 | 0.866 | 0.558 | 0.415 | 0.273 | 0.165 | 0.175 | 0.669 | 0.578 | 0.079 | ||
| Roseola | 0.355 | 0.792 | 0.277 | 0.283 | 0.524 | 0.245 | 0.568 | 0.794 | 0.547 | 0.623 | 0.354 | |
| Chickenpox | 0.315 | 0.219 | 0.462 | 0.836 | 0.113 | 0.151 | 0.121 | 0.736 | 0.734 | 0.397 | 0.142 | |
| Diarrhea | 0.787 | 0.338 | 0.404 | 0.171 | 0.252 | 0.615 | 0.529 | 0.423 | 0.824 | 0.391 | 0.397 | |
| Thrush in the mouth or diaper area | 0.058 | 0.693 | 0.686 | 0.442 | 0.512 | 0.438 | 0.158 | 0.757 | 0.201 | 0.399 | ||
| Urinary tract infection | 0.937 | 0.817 | 0.409 | 0.981 | 0.727 | 0.739 | 0.192 | 0.667 | 0.173 | 0.459 | 0.194 | |
| Worm infection | 0.706 | 0.886 | 0.925 | 0.411 | 0.414 | 0.350 | 0.496 | 0.880 | 0.321 | 0.344 | 0.099 | |
| Scarlet fever | 0.230 | 0.642 | 0.572 | 0.628 | 0.693 | 0.862 | 0.369 | 0.508 | 0.592 | 0.353 | 0.256 | 0.116 |
| Measles | 0.505 | 0.062 | 0.389 | 0.705 | 0.188 | 0.502 | 0.766 | 0.187 | – | n.a. | 0.613 | 0.115 |
| Mumps | 0.799 | 0.615 | 0.153 | 0.825 | 0.184 | 0.683 | 0.933 | 0.298 | – | 0.612 | 0.571 | |
| Rubella | 0.960 | 0.660 | 0.868 | 0.449 | 0.117 | 0.569 | 0.565 | – | 0.225 | 0.828 | 0.300 | |
| Tuberculosis | 0.108 | 0.290 | 0.751 | 0.590 | 0.978 | 0.447 | 0.622 | 0.107 | ||||
| DTPPHIB | 0.568 | 0.620 | 0.698 | 0.667 | 0.854 | 0.079 | 0.647 | 0.279 | 0.981 | n.a. | n.a. | |
| Hepatitis B | 0.129 | 0.671 | 0.463 | 0.555 | 0.783 | 0.661 | 0.931 | 0.799 | 0.166 | |||
| MMR | 0.299 | 0.709 | 0.526 | 0.559 | 0.313 | 0.669 | 0.933 | 0.367 | 0.078 | n.a. | 0.065 | |
| Vaccinations | 0.668 | 0.806 | 0.509 | 0.220 | 0.651 | 0.347 | 0.536 | 0.901 | 0.144 | 0.072 | 0.698 | |
| Infections | 0.669 | 0.944 | 0.800 | 0.501 | 0.583 | 0.953 | 0.323 | 0.464 | 0.389 | 0.630 | ||
ADV, adenovirus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, human herpesvirus 6; HIB, Haemophilus influenzae type b; hPIV-3, human parainfluenza virus 3; hRSV, human respiratory syncytial virus; HSV, herpes simplex virus; MMR, combined vaccination against mumps, measles, and rubella; –, No p-value calculated, since no observation in this category; n.a., not available, since only non-specific effects are analyzed; bold values indicates p <0.05.
Normalized and standardized antibody titers of children; reported p-value by ANOVA.
Five categories for exposures: only in first year, only in second year, in both years, missing values, and in neither of the 2 years of age (reference group); respectively for reported infectious disease or obtained vaccination.
Includes pneumonia, otitis media, obstruct or spastic bronchitis, respiratory diseases, and bronchitis.
Only asked in children aged 12–24 months.
Only asked in children aged 19–24 months.
Includes vaccination against diphtheria, tetanus, polio, pertussis, and HIB.
Vaccination/infection ever during pregnancy vs. vaccination/infection never during pregnancy (dichotomized coded).
Only IgG titers of children with corresponding vaccination; children with corresponding infection were excluded.
While the specific viruses can cause respiratory infections and lead to a pseudocroup, they are not their single or most common cause, and therefore, the exposure were kept in the analysis (none displayed a significant association with the respective IgG titer).
Adjusted associations between vaccinations, infections, and exposures during pregnancy and IgG titers of participants in the LISA study.
| Chickenpox (31) | 1. | 0.441 | 0.082, 0.799 | 0.016 | |
| Chickenpox (65) | 2. | 0.218 | −0.035, 0.472 | 0.092 | |
| Chickenpox ( | 1. and 2. | −0.920 | −1.887, 0.046 | 0.062 | |
| Vaccination against DTPPHIB | 1. | −0.367 | −0.593, −0.141 | 0.002 | |
| Vaccination against DTPPHIB | 2. | −0.441 | −2.363, 1.481 | 0.652 | |
| Vaccination against hepatitis B (131) | 1. | −0.323 | −0.550, 0.097 | 0.005 | |
| Vaccination against hepatitis B (68) | 2. | 0.065 | −0.198, 0.328 | 0.629 | |
| Vaccination against hepatitis B (414) | 1. and 2. | 0.167 | 0.005, 0.339 | 0.057 | |
| Vaccination against tuberculosis (139) | 1. | −0.282 | −0.478, −0.087 | 0.005 | |
| Vaccination against tuberculosis (5) | 2. | −0.708 | −1.559, 0.143 | 0.103 | |
| Vaccination against tuberculosis (12) | 1. and 2. | −0.250 | −0.815, 0.314 | 0.385 | |
| Vaccination against MMR (23) | 1. | 0.259 | −0.194, 0.713 | 0.262 | |
| Vaccination against MMR (700) | 2. | 0.202 | 0.038, 0.367 | 0.016 | |
| Vaccination against MMR (61) | 1. and 2. | −0.017 | −0.314, 0.280 | 0.909 | |
| Thrush (169) | 1. | 0.020 | −0.153, 0.193 | 0.818 | |
| Thrush (92) | 2. | 0.359 | 0.140, 0.579 | 0.001 | |
| Thrush (71) | 1. and 2. | 0.037 | −0.209, 0.283 | 0.770 | |
| Vaccination against tuberculosis (83) | 1. | 0.382 | 0.120, 0.645 | 0.004 | |
| Vaccination against tuberculosis (1) | 2. | −1.429 | −3.389, 0.532 | 0.153 | |
| Vaccination against tuberculosis (8) | 1. and 2. | −0.054 | −0.773, 0.666 | 0.883 | |
| Infection (65) | During pregnancy vs. not | −0.279 | −0.545, −0.014 | 0.039 |
HHV-6, human herpesvirus 6; HIB: Haemophilus influenzae type b; hRSV, human respiratory syncytial virus; MMR, combine vaccination against mumps measles and rubella.
For two antibodies (hPIV-3 and HSV) the final model had <10 observations in the exposed group; these significant results are not presented.
Multivariable linear regression, backward selection of independent variables of normalized and standardized IgG antibody titers; only antibody titers were considered with evidence of seropositivity.
1., exposure only in first year of age; 2., exposure only in second year of age; 1. and 2., exposure only in first 2 years of age; reference group: children with no corresponding exposure in the first 2 years of age.
Regression coefficients are presented in units of standard deviation of the standard normal distribution; adjusted for sex of child, age of the mother at birth, education level of the parents, and study center.
Only IgG titers of vaccinated children; children with corresponding infection were excluded.
In addition adjusted for smoking during pregnancy.
DTPPHIB: vaccination against diphtheria, tetanus, pertussis, HIB and polio; no estimator for “no vaccination” exist, since no measles antibody titer could be detected, accordingly the category “vaccination in both years (1. and 2.)” was selected as reference group.
Binary coded.